UA116615C2 - Застосування ондансетрону у лікуванні хвороби чи розладу, пов'язаних з алкоголем - Google Patents

Застосування ондансетрону у лікуванні хвороби чи розладу, пов'язаних з алкоголем

Info

Publication number
UA116615C2
UA116615C2 UAA201300520A UAA201300520A UA116615C2 UA 116615 C2 UA116615 C2 UA 116615C2 UA A201300520 A UAA201300520 A UA A201300520A UA A201300520 A UAA201300520 A UA A201300520A UA 116615 C2 UA116615 C2 UA 116615C2
Authority
UA
Ukraine
Prior art keywords
alcohol
disorders
diagnosis
treatment
molecular genetic
Prior art date
Application number
UAA201300520A
Other languages
English (en)
Inventor
Банколе А. Джонсон
Original Assignee
Юніверсіті Оф Вірджінія Петент Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юніверсіті Оф Вірджінія Петент Фаундейшн filed Critical Юніверсіті Оф Вірджінія Петент Фаундейшн
Publication of UA116615C2 publication Critical patent/UA116615C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Addiction (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)

Abstract

Винахід стосується застосування ондансетрону у лікуванні хвороб чи розладу, пов'язаних з алкоголем, причому у пацієнта ген HTR3А та/або ген HTR3B мають певні генотипи (AG генотип rs1150226; AC генотип rs17614942; GG генотип rs1176713).
UAA201300520A 2010-07-02 2011-07-01 Застосування ондансетрону у лікуванні хвороби чи розладу, пов'язаних з алкоголем UA116615C2 (uk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36120310P 2010-07-02 2010-07-02
US201161429416P 2011-01-03 2011-01-03
US201161488328P 2011-05-20 2011-05-20
PCT/US2011/042823 WO2012003462A1 (en) 2010-07-02 2011-07-01 Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence

Publications (1)

Publication Number Publication Date
UA116615C2 true UA116615C2 (uk) 2018-04-25

Family

ID=45402467

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201300520A UA116615C2 (uk) 2010-07-02 2011-07-01 Застосування ондансетрону у лікуванні хвороби чи розладу, пов'язаних з алкоголем

Country Status (17)

Country Link
US (8) US8753815B2 (uk)
EP (2) EP2588630A4 (uk)
AU (1) AU2011274355B2 (uk)
CA (1) CA2804174A1 (uk)
CY (1) CY1120057T1 (uk)
DK (1) DK2801625T3 (uk)
EA (1) EA024450B1 (uk)
ES (1) ES2664083T3 (uk)
HR (1) HRP20180193T1 (uk)
HU (1) HUE035574T2 (uk)
IL (2) IL278149B2 (uk)
LT (1) LT2801625T (uk)
NZ (3) NZ621352A (uk)
PL (1) PL2801625T3 (uk)
SI (1) SI2801625T1 (uk)
UA (1) UA116615C2 (uk)
WO (1) WO2012003462A1 (uk)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10533226B2 (en) 2008-02-28 2020-01-14 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
US10603307B2 (en) 2010-07-02 2020-03-31 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
US11351154B2 (en) 2011-09-09 2022-06-07 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138811A1 (en) * 2012-03-16 2013-09-19 Life Of Purpose, Llc Niche-specific treatment infrastructure continuum
US11610144B2 (en) * 2018-02-02 2023-03-21 BioRealm LLC Biosignature discovery for substance use disorder using statistical learning

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA219554A (en) 1922-06-13 Edward A. Taft Knot tying implement
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5550021A (en) 1990-02-07 1996-08-27 Board Of Regents, The University Of Texas System Allelic diagnosis of susceptibility to compulsive disorder
RU2075978C1 (ru) 1994-03-21 1997-03-27 Владислав Ефимович Шофер Способ лечения больных хроническим алкоголизмом
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
EP0945133A1 (en) 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US20040167164A1 (en) 1998-05-05 2004-08-26 Jose Pozuelo Compositions and methods for treating particular chemical addictions and mental illnesses
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
CA2362533A1 (en) 1999-02-22 2000-08-31 Variagenics, Inc. Gene sequence variations with utility in determining the treatment of disease
KR100697485B1 (ko) 1999-02-24 2007-03-20 유니버시티 오브 신시내티 충동 자제 이상 치료를 위한 설파메이트 유도체의 용도
US6740038B2 (en) 2000-09-29 2004-05-25 New Health Sciences, Inc. Systems and methods for assessing vascular effects of a treatment
US7122308B2 (en) 2001-02-16 2006-10-17 Centre For Addiction And Mental Health Detection of antidepressant induced mania
US7033771B2 (en) 2001-05-08 2006-04-25 Takeda Pharmaceutical Company Limited Use of insulin response modulators in the treatment of diabetes and insulin resistance
EP1262196A3 (en) 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
JP2005508888A (ja) 2001-08-14 2005-04-07 バイオティ セラピーズ コーポレイション アルコール依存症またはアルコール中毒を治療する方法
EP1434875A4 (en) 2001-08-21 2004-12-22 Smithkline Beecham Corp GENE POLYMORPHISMS AND TREATMENT RESPONSE
US20060173064A1 (en) 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US20030114475A1 (en) 2001-10-31 2003-06-19 Addiction Therapies, Inc. Methods for the treatment of addiction
AU2003240253A1 (en) * 2002-05-15 2003-12-02 Epidauros Biotechnologie Ag Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications
AU2003237657A1 (en) * 2002-05-24 2003-12-12 Epidauros Biotechnologie Ag Means and methods for improved treatment using "setrones"
AT414215B (de) 2003-02-12 2006-10-15 Peter Ziger Anlage zur plasmaprozessierung
JP4343948B2 (ja) 2003-04-29 2009-10-14 オレキシジェン・セラピューティクス・インコーポレーテッド 体重減少に影響を及ぼすための組成物
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7163969B2 (en) 2003-10-14 2007-01-16 Stockhausen, Inc. Superabsorbent polymer aqueous paste and coating
US20050245461A1 (en) 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
WO2007009691A2 (en) 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti -addictive agent
WO2007039123A2 (en) 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
BRPI0616344A2 (pt) 2005-09-26 2011-06-14 Avigen Inc mÉtodo para o tratamento de dependÊncia quÍmica e comportamental
US20070196841A1 (en) * 2006-01-20 2007-08-23 Gualberto Ruano Physiogenomic method for predicting response to diet
WO2007095580A2 (en) 2006-02-15 2007-08-23 The Regents Of The University Of California Treatment response in generalized social phobia
US20070292880A1 (en) 2006-05-05 2007-12-20 Robert Philibert Compositions and methods for detecting predisposition to a substance use disorder or to a mental illness or syndrome
US20080004260A1 (en) 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
AU2007333656A1 (en) 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
CA2677205A1 (en) 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
US20080228700A1 (en) 2007-03-16 2008-09-18 Expanse Networks, Inc. Attribute Combination Discovery
WO2009010837A2 (en) 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
WO2009026381A2 (en) 2007-08-21 2009-02-26 University Of Virginia Patent Foundation Method, computer program product and system for individual assessment of alcohol sensitivity
JP2010537990A (ja) 2007-08-27 2010-12-09 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール中毒および薬物嗜癖の処置のための医薬の組み合わせ
BRPI0908425B8 (pt) 2008-02-28 2021-05-25 Univ Of Virgina Patent Foundation métodos para predizer uma predisposição para desenvolver alcoolismo, e para predizer uma resposta para o tratamento contra alcoolismo, e, uso de um antagonista do receptor de serotonina 5-ht3
US20090269773A1 (en) 2008-04-29 2009-10-29 Nodality, Inc. A Delaware Corporation Methods of determining the health status of an individual
AU2010242062A1 (en) 2009-05-01 2011-11-24 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
UA116615C2 (uk) 2010-07-02 2018-04-25 Юніверсіті Оф Вірджінія Петент Фаундейшн Застосування ондансетрону у лікуванні хвороби чи розладу, пов'язаних з алкоголем
EA027743B1 (ru) 2011-09-09 2017-08-31 Юниверсити Оф Вирджиния Пэтент Фаундейшн Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
US10997121B1 (en) 2020-07-17 2021-05-04 Snowflake Inc. Attachable-and-detachable database sessions

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10533226B2 (en) 2008-02-28 2020-01-14 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
US10619209B2 (en) 2008-02-28 2020-04-14 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of opioid-related disorders
US10995374B2 (en) 2008-02-28 2021-05-04 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of opioid-related disorders
US11905562B2 (en) 2008-02-28 2024-02-20 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of opioid-related disorders
US10603307B2 (en) 2010-07-02 2020-03-31 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
US11116753B2 (en) 2010-07-02 2021-09-14 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
US11324723B2 (en) 2010-07-02 2022-05-10 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
US11957664B2 (en) 2010-07-02 2024-04-16 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
US11351154B2 (en) 2011-09-09 2022-06-07 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence

Also Published As

Publication number Publication date
EP2588630A4 (en) 2013-12-25
NZ621356A (en) 2015-08-28
US11324723B2 (en) 2022-05-10
US9539242B2 (en) 2017-01-10
US20200316028A1 (en) 2020-10-08
CA2804174A1 (en) 2012-01-05
HUE035574T2 (en) 2018-05-28
IL278149B2 (en) 2024-03-01
US11957664B2 (en) 2024-04-16
AU2011274355A1 (en) 2013-01-24
EP2588630A1 (en) 2013-05-08
WO2012003462A1 (en) 2012-01-05
US20170239222A1 (en) 2017-08-24
EP2801625A1 (en) 2014-11-12
IL262874B (en) 2021-02-28
IL262874A (en) 2018-12-31
US8753815B2 (en) 2014-06-17
US20230241032A1 (en) 2023-08-03
US20230263776A1 (en) 2023-08-24
US11116753B2 (en) 2021-09-14
ES2664083T3 (es) 2018-04-18
US20130012559A1 (en) 2013-01-10
EP2801625B1 (en) 2017-11-01
IL278149A (en) 2020-11-30
WO2012003462A4 (en) 2012-03-22
IL278149B1 (en) 2023-11-01
SI2801625T1 (en) 2018-04-30
PL2801625T3 (pl) 2018-06-29
HRP20180193T1 (hr) 2018-04-06
NZ621352A (en) 2015-08-28
CY1120057T1 (el) 2018-12-12
US10603307B2 (en) 2020-03-31
EA024450B1 (ru) 2016-09-30
EA201390017A1 (ru) 2013-06-28
US20140288139A1 (en) 2014-09-25
LT2801625T (lt) 2018-03-12
US20230014787A1 (en) 2023-01-19
US20210023058A1 (en) 2021-01-28
AU2011274355B2 (en) 2016-10-27
DK2801625T3 (en) 2018-02-05
NZ605709A (en) 2014-08-29

Similar Documents

Publication Publication Date Title
JP7096592B2 (ja) Ｊａｋ阻害剤およびこれらの利用
CY1120057T1 (el) Μοριακη γενετικη προσεγγιση της θεραπειας και διαγνωσης της εξαρτησης απο το αλκοολ και τα ναρκωτικα
EP3498729A3 (en) Therapeutic targets for alzheimer's disease
MX371228B (es) Anticuerpos antiperiostina, kits, composiciones y su uso en la medición de periostina total.
MX2012010418A (es) Inhibidores syk de imidazopiridinas.
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
TN2013000256A1 (en) Methods and drug products for treating alzheimer's disease
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
MY164376A (en) Phosphospecific antibodies recognizing tau
UA113186C2 (xx) Макроциклічні інгібітори lrrk2 кінази
WO2012142301A3 (en) Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
MY164579A (en) Safe and functional humanized antibodies
WO2015118537A3 (en) Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
MX2013015409A (es) Diagnostico de la enfermedad de alzheimer.
EA201390653A1 (ru) Aa антагонисты как усилители когнитивной и моторной функций
MY196998A (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
AU2012313353A8 (en) Screening method
HK1203190A1 (en) Compounds for use in imaging, diagnosing and or treatment of diseases of the central nervous system
WO2012103282A3 (en) Methods and compositions for treating alzheimer's disease
WO2012061808A3 (en) Neuropsychiatric test reports
Azmanov et al. Focal epilepsy of probable temporal lobe origin in a Gypsy family showing linkage to a novel locus on 7p21. 3
Aminkeng WDR45 mutations define a novel disease entity-Static Encephalopathy of Childhood with Neurodegeneration in Adulthood.